Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial
-
Published:2024-06-28
Issue:
Volume:
Page:
-
ISSN:1078-8956
-
Container-title:Nature Medicine
-
language:en
-
Short-container-title:Nat Med
Author:
Shi Yuankai, Guo Wei, Wang Wei, Wu Yunteng, Fang Meiyu, Huang Xiaoming, Han Ping, Zhang Qingyuan, Dong Pin, Zhou Xiaohong, Peng Hanwei, Hu Chunhong, Chen Xiaopin, Zhang Shurong, Chang Zhiwei, Li Xiaojiang, Ding Yuhai, Qu Song, Jing Shanghua, Zhang Songnan, Gui Lin, Sun Yan, Wang Lin, Liu Yanyan, Wu Hui, Li Guoqing, Fu Zhichao, Shi Jianhua, Jiang Hao, Bai Yuansong, Cui Jiuwei, Zheng Yulong, Cui Wei, Jia Xiaojing, Zhai Limin, Cai QingqingORCID, Xiong Deming, Wu Yunong, Cao Junning, Wu Rong, Hu Guangyuan, Peng Liang, Xie LiangzhiORCID, Gai Wenlin, Wang Yan, Su Yuehua
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Gormley, M., Creaney, G., Schache, A., Ingarfield, K. & Conway, D. I. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br. Dent. J. 233, 780–786 (2022). 2. Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024). 3. Xia, C. et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. 135, 584–590 (2022). 4. Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer. Nat. Rev. Cancer 18, 269–282 (2018). 5. Braakhuis, B. J., Brakenhoff, R. H. & Leemans, C. R. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann. Oncol. 23, x173–x177 (2012).
|
|